- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07718334
Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective
Impact of a Mobile Application-Based Medication Reminder on Treatment Adherence Among Patients With Chronic Diseases and Memory Impairment: A Nursing Leadership Perspective - A Quasi Experimental Study
연구 개요
상세 설명
Improving medication adherence in patients with chronic illnesses and cognitive decline is a key priority in healthcare management and nursing administration. This quasi-experimental study utilizes a pretest-posttest design to examine the effectiveness of a mobile application-based reminder system designed specifically for patients experiencing memory impairment.
Participants will be selected based on specific inclusion criteria, including being diagnosed with a chronic disease and exhibiting mild-to-moderate memory impairment. Baseline assessments (pretest) will be conducted to measure initial medication adherence levels, patient demographics, and health status. Following the baseline phase, the intervention will be introduced, where participants will utilize the mobile application to receive automated medication alerts and reminders over a specified period. Evaluation (posttest) will be performed post-intervention to analyze changes in adherence rates. The findings are expected to provide insights into how nursing leadership can leverage mobile health (mHealth) technology to design supportive care pathways, enhance patient independence, and reduce clinical complications associated with poor treatment adherence.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Asmaa Elwan Hassan, PhD
- 전화번호: +201063776424
- 이메일: asmaaelwan@mans.edu.eg
연구 연락처 백업
- 이름: Mona Ahmed Gabr, PhD
- 전화번호: 201097898593
연구 장소
-
-
Dakahlia Governorate
-
Gamasa, Dakahlia Governorate, 이집트
- 모병
- Outpatient Clinics, Delta University for Science and Technology
-
연락하다:
- Asmaa Elwan Hassan, PhD
- 전화번호: +201063776424
- 이메일: asmaaelwan@mans.edu.eg
-
연락하다:
- Mona Ahmed Gabr, PhD
-
-
Kafr el-Sheikh Governorate
-
Kafr ash Shaykh, Kafr el-Sheikh Governorate, 이집트
- 모병
- Outpatient Clinics, Kafr El-Sheikh Hospital
-
연락하다:
- Asmaa Elwan Hassan, PhD
- 전화번호: +201063776424
- 이메일: asmaaelwan@mans.edu.eg
-
연락하다:
- Mona Ahmed Gabr, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Patients diagnosed with one or more chronic diseases requiring regular long-term medication.
- Patients exhibiting mild-to-moderate memory impairment or cognitive decline as screened by the Mini-Mental State Examination (MMSE).
- Patients who personally own and are capable of operating a smartphone or have a primary caregiver willing to manage the mobile application.
- Patients aged 18 years and older.
- Patients who provide voluntary informed consent to participate in the study.
Exclusion Criteria:
- Patients with severe cognitive impairment or advanced dementia who cannot interact with mobile technology even with caregiver assistance.
- Patients with severe acute clinical complications or unstable psychiatric conditions.
- Patients participating in another concurrent clinical trial or study targeting medication adherence
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Mobile Application Group
Participants in this single-group study will receive training on and utilize a customized mobile application-based medication reminder designed to support adherence to their therapeutic regimens.
|
The intervention consists of a mobile application specifically designed to support medication adherence.
It features automated push notifications, customized reminder alerts matching prescribed medication schedules, and tracking logs.
Participants will be instructed on how to install, configure, and use the application on their personal smartphones.
The system is designed to provide immediate prompts to overcome memory-related adherence barriers.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Medication Adherence (MMAS-8)
기간: Baseline (pre-intervention) and 3 months post-intervention
|
Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8).
This self-reported tool evaluates patients' behaviors regarding taking their prescribed chronic medications.
Total scores range from 0 to 8, where a score of 8 indicates high adherence, 6 to <8 indicates medium adherence, and <6 indicates low adherence.
|
Baseline (pre-intervention) and 3 months post-intervention
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Medication Adherence: Medication Possession Ratio (MPR)
기간: 3 months post-intervention
|
Medication Possession Ratio (MPR) will be calculated using pharmacy refill records to determine the proportion of time the patient has access to their prescribed medication during the study period.
Total scores will range from 0 to 1 (or 0% to 100%), with higher values indicating better adherence.
|
3 months post-intervention
|
|
Objective Medication Adherence: Proportion of Days Covered (PDC)
기간: 3 months post-intervention
|
Proportion of Days Covered (PDC) will be assessed using pharmacy refill records to measure the percentage of days the patient covered their prescribed medication dosage over the study duration.
Total scores will range from 0 to 1 (or 0% to 100%), where higher values reflect superior medication adherence.
|
3 months post-intervention
|
|
Cognitive Function Status (MMSE)
기간: Baseline
|
Cognitive impairment levels will be screened using the Mini-Mental State Examination (MMSE) to classify the severity of cognitive/memory impairment among participants.
|
Baseline
|
|
Perceived Nursing Care and Leadership Support
기간: 3 months post-intervention.
|
Evaluated using the Nursing Care and Leadership Support Assessment Tool to measure patient satisfaction and perception of the supportive role played by nursing leadership during the application-based program.
|
3 months post-intervention.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- DFM-IRB 00012367- 26-04-001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 질환에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.아직 모집하지 않음Crohn & amp;#39; s | Crohn & amp;#39; s Disease (CD)
-
Vanderbilt University Medical CenterTakeda Pharmaceuticals U.S.A., Inc.모집하지 않고 적극적으로염증성 장질환(IBD) | 궤양성 대장염(UC) | Crohn & amp;#39; s Disease (CD)미국
-
Kaohsiung Medical University아직 모집하지 않음폐 선암종 | 폐암(진단) | Condition/Disease
-
Nandakumar NarayananNational Institute of Neurological Disorders and Stroke (NINDS)초대로 등록
-
UNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of Health모집하지 않고 적극적으로
-
Novartis Pharmaceuticals모병류마티스 관절염 (RA) 및 Sjögren 's Disease (SJD)스페인, 프랑스, 독일, 싱가포르
-
University of PennsylvaniaEUSA Pharma, Inc.; Castleman Disease Collaborative Network모병캐슬맨병 | 캐슬맨병 | 거대 림프절 과형성 | 혈관여포 림프 증식증 | 혈관여포 림프절 과형성 | 혈관여포성 림프종 과형성 | GLNH | 과형성, 거대 림프절 | 림프절 과형성, 거인미국